

MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE EUROPEAN RNA LEADERS CONGRESS IN BALE

Montpellier, March 13, 2023 - 8:00am – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates with Aonys®, its proprietary buccal nanodroplet active ingredient administration technology is pleased to announce its participation in the second European RNA Leaders Congress which will take place in Basel on March 15 and 16.

Medesis Pharma teams will be present to meet with key players in the RNA field and discuss the latest advances in RNA chemistry, clinical updates and potential collaborations in the development of RNA-based therapies.

They will also present a scientific poster at the conference : **Aonys® technology - Buccal administration for siRNA systemic delivery** describing pharmacokinetic and pharmacological data supporting the potential of the Aonys® drug delivery technology to deliver unmodified siRNAs after oral administration for the treatment of neurodegenerative diseases including its potential application in the genetic treatment of Huntington's disease and in oncology to inhibit the expression of an abnormal or overexpressed gene.

Medesis Pharma's proprietary technology, Aonys®, is an assembly of lipid components that spontaneously self-structure into a "water-in-oil" microemulsion. Aonys® allows the administration of water-soluble pharmaceutical active ingredients. The product is deposited on the mucosa of the mouth and then transported by lipoproteins and released directly into the cytoplasm of cells throughout the membrane using cell lipoprotein receptors, with crossing of the Blood-Brain Barrier (BBB). Studies on native siRNAs encapsulated in Aonys® have demonstrated crossing of BBB, intracellular delivery, efficient reduction of the target gene, and associated phenotypic results in mouse models.



The second edition of RNA Leaders Europe brings together more than 450 professionals from the biotech, pharmaceutical, investment and research science industries.

The congress covers the entire ecosystem and offers conferences, discussions and guests from all RNA disciplines, bringing together the most important decision-makers from RNA Biotechs and large pharmaceutical companies.

For more information:

- [Download Medesis Pharma's poster](#)
- [Visit RNA Leaders congress website](#)

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 72 patents, the result of 19 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information:

www.medesispharma.com

MEDESIS PHARMA

Tessa Olivato

Tel: +33 4 67 03 03 96

contact@medesispharma.com

CALYPTUS

Marie Calleux

Tel : +33 1 53 65 68 66

medesispharma@calyptus.net